#United States #Atlanta #SK Life Science #Epilepsy #AES Meeting

SK Life Science Hosts Symposium on Epilepsy Treatment

SK Life Science, Inc., a prominent entity in central nervous system (CNS) disorder treatments and a subsidiary of SK Biopharmaceuticals Co., Ltd., is set to host an educational symposium titled "Illuminating the Path to Added Seizure Reduction." This major event will occur during the 2025 American Epilepsy Society (AES) Annual Meeting, taking place in Atlanta, Georgia.

Symposium Details

The symposium is scheduled for Friday, December 5, 2025, at the Omni Atlanta Hotel at Centennial Park, specifically in Grand Ballroom D. Doors will open at 6:00 PM, and the presentations will commence at 6:30 PM.

This symposium promises to be an insightful exploration of current trends and real-world applications in epilepsy treatment, co-led by respected epileptologists from various esteemed institutions, including:

• - Pavel Klein, MB BChir, FAAN, FAES—Mid-Atlantic Epilepsy and Sleep Center, Bethesda, Maryland
• - Danielle Becker, MD, MS, FAES—The Ohio State University Wexner Medical Center, Columbus, Ohio
• - Raman Sankar, MD, PhD, FAAN, FAES—David Geffen School of Medicine at UCLA, Los Angeles, California
• - John M. Stern, MA, MD, FAES, FANA, FAAN—David Geffen School of Medicine at UCLA, Los Angeles, California

Key Focus Areas

The symposium aims to delve into the evolving landscape of epilepsy treatment. Attendees will gain important insights into the role that third-generation antiseizure medications (ASMs) play in enhancing seizure control for patients suffering from epilepsy. The agenda comprises three primary objectives:
1. Evolution of Treatment Approaches: Understanding the advancements in treatment methodologies with a focus on third-generation ASMs.
2. Real-World Patient Case Studies: Analyzing real-life scenarios to assess how clinical decisions influence patient outcomes.
3. Clinician Perspective Shifts: Evaluating changing views among healthcare providers regarding treatment options that can lead to seizure freedom.

Matt Linkewich, Chief Commercial Officer at SK Life Science, emphasized the importance of educational initiatives in improving epilepsy care, stating, "Education and collaboration are essential to advancing the care of people living with epilepsy. Through programs like this symposium, we aim to provide clinicians with the latest clinical insights and real-world data to help them make informed treatment decisions, ultimately supporting our shared goal of helping more patients achieve seizure freedom."

Registration Information

For those interested in attending, pre-registration is available at AES 2025 Registration.

About SK Life Science, Inc.

Headquartered in Paramus, New Jersey, SK Life Science, Inc. is actively involved in developing innovative treatments not only for CNS disorders but also in oncology, with multiple compounds in their pipeline. Their approach employs cutting-edge techniques including target-based drug discovery and high-throughput screening to enhance research and development efforts.

SK Biopharmaceuticals Co., Ltd., the parent company, is a part of the SK Group, a major South Korean conglomerate committed to driving innovation across various industries, including pharmaceuticals, energy, and materials. With a focus on sustainability and long-term growth, SK is continuously advancing its capabilities in the global biopharmaceutical landscape.

For additional information regarding SK Life Science, visit their official website at www.SKLifeScienceInc.com.